Rasagiline: a review of its use in the management of Parkinson's disease.

Rasagiline (Azilect) is a novel, selective, irreversible second-generation inhibitor of monoamine oxidase type B (MAO-B). It is administered orally once daily and is approved in the US, Canada, Mexico, Israel and the EU for use as monotherapy and as adjunct therapy in the treatment of Parkinson's disease. Results of well designed clinical studies indicate that rasagiline is effective as initial monotherapy and improves Parkinson's symptomatology in patients with early Parkinson's disease. In addition, when administered in conjunction with levodopa, in patients with moderate to advanced disease and motor fluctuations, rasagiline reduces mean daily 'off' time and increases daily 'on' time without troublesome dyskinesias, compared with controls. Rasagiline is generally well tolerated as monotherapy and adjunctive therapy and is administered once daily. Thus, rasagiline, administered as a simple and convenient dosage regimen, is a well tolerated and effective option for monotherapy in patients with early Parkinson's disease and for adjunctive therapy in patients with moderate to advanced disease.
AuthorsVicki Oldfield, Gillian M Keating, Caroline M Perry
JournalDrugs (Drugs) Vol. 67 Issue 12 Pg. 1725-47 ( 2007) ISSN: 0012-6667 [Print] New Zealand
PMID17683172 (Publication Type: Journal Article, Review)
Chemical References
  • Antiparkinson Agents
  • Indans
  • Monoamine Oxidase Inhibitors
  • rasagiline
  • Levodopa
  • Animals
  • Antiparkinson Agents (adverse effects, pharmacokinetics, pharmacology, therapeutic use)
  • Drug Therapy, Combination
  • Humans
  • Indans (adverse effects, pharmacokinetics, pharmacology, therapeutic use)
  • Levodopa (therapeutic use)
  • Monoamine Oxidase Inhibitors (adverse effects, pharmacokinetics, pharmacology, therapeutic use)
  • Parkinson Disease (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: